LMB-2

LMB-2 is a recombinant immunotoxin that targets CD25-positive cells, particularly in hematologic malignancies. It consists of an anti-CD25 antibody fragment (anti-Tac(Fv)) fused to a truncated Pseudomonas exotoxin (PE38)[1][5]. This drug has been investigated primarily for treating various CD25-positive cancers, including hairy cell leukemia, adult T-cell leukemia-lymphoma, cutaneous T-cell lymphoma, and other hematologic malignancies[1][5][6]. ## Mechanism of Action LMB-2 works by selectively targeting cancer cells that express CD25 (also known as the interleukin-2 receptor alpha chain or IL2RA) on their surface[1][3]. The antibody portion of LMB-2 binds to CD25, allowing the toxin portion to enter and kill the cancer cells. Laboratory experiments have shown that LMB-2 can effectively kill CD25-containing cells outside the human body and has demonstrated significant tumor reduction in mouse models at doses similar to those used in human trials[3]. ## Clinical Development The drug has undergone several clinical trials: - A Phase I trial evaluated LMB-2 in 35 patients with CD25-positive hematologic malignancies who had failed standard and salvage therapies. The maximum tolerated dose was established at 40 μg/kg administered intravenously every other day for three doses[5]. - Phase II trials have investigated LMB-2 for specific conditions including hairy cell leukemia and adult T-cell leukemia[1][6][9]. - A notable Phase II trial combined LMB-2 with cyclophosphamide and fludarabine to prevent antidrug antibody formation and rapid disease progression between treatment cycles in adult T-cell leukemia patients[6]. ## Clinical Efficacy LMB-2 has shown promising results in clinical trials: - In the Phase I trial, one hairy cell leukemia patient achieved a complete remission lasting at least 20 months, and seven partial responses were observed across various hematologic malignancies[5]. - All four hairy cell leukemia patients in the Phase I trial responded to treatment[5]. - In the Phase II trial for adult T-cell leukemia using LMB-2 after cyclophosphamide and fludarabine, 6 of 10 evaluable leukemic patients (60%) achieved complete remission and 2 (20%) achieved partial remission. All 5 patients with >25% leukemic cells achieved complete remission[6]. ## Administration and Dosing LMB-2 is administered intravenously, typically every other day for three doses (days 1, 3, and 5) in each treatment cycle[3][5]. The maximum tolerated dose was determined to be 40 μg/kg[5]. In some protocols, patients may receive up to 6 cycles of treatment at 3-4 week intervals, depending on disease response and side effects[3][6]. ## Side Effects and Toxicity Common side effects of LMB-2 include: - Transaminase elevations (liver enzyme increases) - Fever - Diarrhea - Cardiomyopathy (at higher doses) - Capillary leak syndrome (non-dose limiting)[5][6] Most toxicities were transient and reversible. When combined with cyclophosphamide and fludarabine, many of the observed toxicities were attributable to these chemotherapy agents rather than LMB-2 itself[6]. LMB-2 represents an important advancement in targeted cancer therapy as one of the first recombinant immunotoxins to demonstrate significant clinical responses in cancer patients.

Brand names

LMB-2LMB2LMB 2

Other names

anti-CD25 recombinant immunotoxinanti-CD-25 recombinant immunotoxinanti-CD 25 recombinant immunotoxinanti-Tac(Fv)-PE38anti-Tac immunotoxin